Home Newsfeeds Exane BNP Paribas Initiates Coverage On TransUnion with Neutral Rating, Announces Price Target of $64.5

Exane BNP Paribas Initiates Coverage On TransUnion with Neutral Rating, Announces Price Target of $64.5

Exane BNP Paribas analyst Andy Grobler initiates coverage on TransUnion (NYSE:TRU) with a Neutral rating and announces Price Target of $64.5.

byBenzinga Newsdesk

January 6, 2023

1 minute read

Exane BNP Paribas analyst Andy Grobler initiates coverage on TransUnion (NYSE:TRU) with a Neutral rating and announces Price Target of $64.5.

EXCLUSIVE: Gene Munster Sees Growth Stocks Rising With Lower Rates, Warns Of AI Hype

By Piero Cingari

April 4, 4:29 PM

Gene Munster, managing partner at Deepwater Asset Management, joined Benzinga's "PreMarket Prep" show Monday to share his outlook for megacap stocks.

AAPL

United Therapeutics Announces Top Line Data From The EXPEDITE Study Of Remodulin Induction Prior To Orenitram Therapy

By Benzinga Newsdesk

October 31, 6:05 AM

short induction of Remodulin® (treprostinil) injection allowed study subjects to reach double the typical doses of Orenitram® (treprostinil) extended-release tablets than patients who did not have a Remodulin

UTHR

Theratechnologies Announces Proposed Public Offering Of Common Shares And Concurrent Private Placement; No Size Or Amount Disclosed

By Benzinga Newsdesk

October 25, 5:03 PM

Theratechnologies Inc. ("Theratechnologies" or the "Company") (NASDAQ:THTX, TSX:TH), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced the launch of a

THTX

ZoomInfo Technologies Shares Climb As It Wields AI, Gears Up For Next Stage Of Growth

By Priya Nigam

June 28, 11:35 AM

Shares of ZoomInfo Technologies Inc (NASDAQ: ZI) climbed in early trading on Wednesday, after the company released new and enhanced product features based on Generati

Exane BNP Paribas Initiates Coverage On TransUnion with Neutral Rating, Announces Price Target of $64.5

Related Posts

EXCLUSIVE: Gene Munster Sees Growth Stocks Rising With Lower Rates, Warns Of AI Hype

United Therapeutics Announces Top Line Data From The EXPEDITE Study Of Remodulin Induction Prior To Orenitram Therapy

Theratechnologies Announces Proposed Public Offering Of Common Shares And Concurrent Private Placement; No Size Or Amount Disclosed

ZoomInfo Technologies Shares Climb As It Wields AI, Gears Up For Next Stage Of Growth